{
    "nctId": "NCT00696072",
    "briefTitle": "Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",
    "officialTitle": "Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population",
    "eligibilityCriteria": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Has histologic or cytologic diagnosis of breast cancer; evidence of unresectable locally recurrent or metastatic disease\n* Has measurable or evaluable-only disease\n* Is female, \u226518 yrs of age, post menopausal or surgically sterile\n* HER2 negative, HR+, ER+ and/or PgR+ breast cancer\n* 0-1 prior chemotherapy regimen for metastatic disease.\n* Prior adjuvant or neoadjuvant chemotherapy completed at least 1 month prior\n* Prior tamoxifen therapy is allowed\n* No AI therapy for \\>1 year without recurrence\n\nExclusion Criteria:\n\n* Pregnant or breast feeding\n* Prior hormonal therapy for metastatic or locally recurrent disease\n* \\>1 chemotherapy regimen for metastatic disease\n* Pleural or pericardial effusion\n* Serious cardiac condition",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}